Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

This publication has 39 references indexed in Scilit:

• Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care
  British Journal of Cancer, 2011
• Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features
  Breast Cancer Research and Treatment, 2010
• Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
  The Lancet Oncology, 2010
• Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
  The Lancet, 2009
• The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
  Breast Cancer Research and Treatment, 2009
• Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93
  Breast Cancer Research and Treatment, 2008
• Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
  New England Journal of Medicine, 2008
• Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer
  JAMA, 2006
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
  The Lancet, 2005
• A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
  New England Journal of Medicine, 2004